Welcome to our dedicated page for Radnostix SEC filings (Ticker: INIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for International Isotopes Inc. (now Radnostix, Inc., ticker INIS) provide detailed insight into the company’s operations, governance, and strategic direction in the radioisotope and theranostics space. As a Texas-incorporated issuer with its stock quoted on the OTCQB marketplace, the company files periodic and current reports under the Securities Exchange Act of 1934.
On this page, users can review current reports on Form 8-K that document material events. Recent 8-K filings describe the legal name change from International Isotopes Inc. to Radnostix, Inc. through a Certificate of Amendment in Texas, along with the rationale that the new name better reflects the company’s broader portfolio of radioisotope, theranostics, and related products, devices, and accessories. Another 8-K outlines an employment agreement with the company’s President and Chief Executive Officer, including compensation terms and equity incentives, and details amendments to the company’s bylaws covering special meetings, advance notice procedures for shareholder proposals and director nominations, advisory directors, indemnification, and insurance.
Filings also address board composition and governance, such as the appointment of an independent director with nuclear pharmacy and radiopharmaceutical manufacturing experience and that director’s role on the audit committee. These disclosures help investors understand oversight structures, independence considerations, and board-level expertise relevant to the company’s radiopharmaceutical and medical device activities.
In addition to 8-Ks, investors can use this page to access the company’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available), which typically include segment information for Theranostics Products, Calibration & Reference Products, Cobalt Products, Medical Devices, and Fluorine Products, along with risk factors and management’s discussion and analysis. Form 4 and other insider transaction reports, when filed, can shed light on equity awards and share transactions by executives and directors.
Stock Titan’s platform enhances these documents with AI-powered summaries that highlight key points from lengthy filings, explain complex sections in plain language, and surface items related to topics such as governance changes, segment disclosures, and compensation arrangements. Real-time updates from EDGAR help ensure that new INIS filings, including 10-Ks, 10-Qs, 8-Ks, and Forms 3 and 4, are quickly available with contextual AI insights for users analyzing this radioisotope-focused company.
International Isotopes Inc. (INIS) reported an insider equity award on Form 4. President & CEO and director Shahe Bagerdjian received 37,500,000 restricted stock units (RSUs) on October 9, 2025 under the company’s Amended and Restated 2015 Incentive Plan.
Each RSU represents a contingent right to receive one share of INIS common stock. The RSUs vest based on milestones tied to the company’s share price and available cash. Following the transaction, the filing shows 37,500,000 derivative securities beneficially owned, held directly, with a stated price of $0 for the RSUs.